Israel’s inoculation campaign is regarded as the world’s fastest, with one dose of the Pfizer/BioNTech vaccine administered to 4.25 million people out of its nine million-strong population since December, according to the latest health ministry figures.
Some 2.88 million people have received the recommended full course of two jabs.
The health ministry said on Saturday the vaccine had proved 95.8 percent effective in preventing coronavirus infection among those vaccinated two weeks after receiving their second shot compared to unvaccinated people, according to data compiled up to February 13.
It added the jab was 99.2 percent effective against serious illness and 98.9 percent effective in preventing death.
For those tested one week after receiving a second jab, the vaccine was 91.9 percent effective against infection, 96.4 percent effective in preventing serious illness, and 94.5 percent in preventing death.
“Our goal is to continue vaccinating all our population aged 16 and up, to reach a wide coverage of the population that will enable us to return to our much missed routines,” health ministry director general Hezi Levi said in a statement Saturday.
The jab developed by US pharma giant Pfizer and its German partner BioNTech is based on novel mRNA technology and was the first vaccine against Covid-19 to be approved in the West late last year.
Israel, which has one of the world’s most sophisticated medical data systems, secured a substantial stock of the Pfizer/BioNTech vaccine by paying above market price and by striking a data-sharing deal with the US company.
COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by manilastandard.net readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of manilastandard.net. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.